Understanding Everest Group’s Innovation Watch

Technological innovation is central to life sciences. It deepens our ability to collect and assess huge amounts of valuable clinical data, accelerating study design and enhancing execution. As one of the fastest-growing technologies of our time, AI is unlocking new ways to drive critical innovation and efficiency throughout the trial lifecycle, becoming a transformative force in our industry.

Through AI integration, clinical research organizations are developing new tools and techniques that allow sponsors to optimize studies, draw deeper insights from data, and deliver life-changing treatments to patients faster than ever before. Selecting the best AI provider to support these studies requires an evaluation framework through which vendors can be benchmarked and assessed.

Everest Group’s new report, Innovation Watch: AI Applications in Clinical Development 2026, takes a deep dive into 18 leading clinical AI providers to assess their progress in developing partnerships and solutions that deliver tangible results.

How Does the Everest Group Innovation Watch Assessment Work?

Everest Group is a leading research firm that supports businesses across a broad range of industries to better understand the state of play and innovate in their respective markets. It has a long relationship with life sciences and has published PEAK Matrix® assessments on key clinical trial technologies including electronic clinical outcome assessments (eCOA) and electronic data capture (EDC).

The organization’s new report assesses clinical AI providers on their use of generative AI and agentic AI, as well as advanced AI solutions in the clinical development space, such as external control arms, digital twins, and trial simulations.

Everest Group has developed a comparative assessment by evaluating these companies based on their market performance and ecosystem drivers. These categories quantify the maturity and scale of each provider’s AI solutions, the investments they’ve made, and the partnerships they’ve formed.

• Market performance addresses the scale and maturity of the providers’ AI integration, analyzing their ability to face challenges including ensuring data quality across fragmented sources, demonstrating return on investment, aligning with evolving regulations, delivering reliable growth, and securing buy-in across the business. This indicates how far their technologies have been developed and their capacity to grow them quickly and sustainably.
• The ecosystem drivers assessment addresses the quality of providers’ AI-based partnerships and investments. Partnerships are key to building a robust AI infrastructure, helping to support various technical and strategic aspects of the business’ offering. Partners like NVIDIA and major cloud platforms are essential for building the fundamental infrastructure to scale data storage, processing, and analysis. Other collaborators may offer access to high-quality data, academic or regulatory credibility, and assistance in developing user-friendly products that give customers the best results. Committed investment is assessed through markers such as product development activity, R&D focus, talent initiatives, and funding.

Based on these results, the providers have been categorized into four quadrants:

• Seekers are at an earlier stage on the AI journey compared to their competitors, with pilot programs that have plenty of room to grow. 
• Fast Followers have built strong solutions that demonstrate maturity and/or scale, but currently have a more limited ecosystem reach.
• Influencers hold greater sway over other enterprises and peers’ thinking on AI, while the scale of their offerings is less mature. 
• Luminaries represent the highest quadrant of the assessment, demonstrating strong maturity and momentum along with a high-performing ecosystem. Luminaries are viewed as leaders in life sciences AI innovation.

This assessment is a vital guide for clinical research organizations seeking an AI partner to support their studies.

Where did the report position Medidata?

Taking into account these different elements of AI infrastructure, Everest Group assessed the 18 providers and placed them relative to each other across its matrix. Medidata was identified as the highest-designated Luminary by Everest Group and the only provider to earn a 100% market adoption score.

“With a comprehensive suite of AI capabilities ranging from data analytics to digital imaging… Medidata is embedding AI across its entire clinical trial platform. Its strong proprietary data assets further strengthen its differentiation in this space.”

– Nisarg Shah, Research Director, Everest Group

The report breaks down our progress in adopting these game-changing AI technologies across our Data, Study, and Patient Experiences. Taken together, these Experiences create a unified Medidata Platform that integrates diverse data sources and streamlines trial processes to deliver faster, more efficient and reliable studies. 

Our Data Experience leverages AI and machine learning to automate processes and ensure data validation and quality assurance across vast volumes of clinical trial data. Everest Group highlighted Clinical Data Studio’s use of AI to detect anomalies, reconcile discrepancies, and mine audit trails to identify key risk areas that might warrant deeper investigation. Rave EDC was recognized for its advanced AI tools that allow users to auto-generate synthetic patients, which can greatly reduce the time it takes to test study builds.

AI is integrated within our Study Experience to streamline study build, site enrollment, and study execution. Everest Group highlights our use of AI to enhance protocol optimization, creating predictive models that help automate study designs and forecast financial and enrollment scenarios. 

The organization also calls out tools within our Patient Experience that vastly simplify workflows, assist raters with AI-driven processing of clinical assessment data, and more.

“By working with a broad ecosystem of partners, developing diverse use cases and applying generative, agentic AI, and advanced AI to address the pressing challenges in clinical development, Medidata is focusing on helping clients realize tangible and increasing returns from their AI investments.”

The highest-designated Luminary position acknowledges the breadth and depth of Medidata’s AI integrations, enhancing the experience for sponsors, sites, and patients and ensuring better outcomes for all involved. This is only the beginning—we’ll continue to grow on this firm foundation, investing in partnerships and delivering mature and scalable solutions that accelerate the delivery of next-generation treatments.

Get complimentary access to the Innovation Watch: AI Applications in Clinical Development 2026 report to start benchmarking providers and explore the full assessment of Medidata AI capabilities.